Revolution Medicines Stock Analysis
| RVMD Stock | USD 37.91 0.69 1.85% |
Revolution Medicines is overvalued with Real Value of 32.39 and Target Price of 72.36. The main objective of Revolution Medicines stock analysis is to determine its intrinsic value, which is an estimate of what Revolution Medicines is worth, separate from its market price. There are two main types of Revolution Medicines' stock analysis: fundamental analysis and technical analysis.
The Revolution Medicines stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Revolution Medicines' ongoing operational relationships across important fundamental and technical indicators.
Revolution | Build AI portfolio with Revolution Stock |
Revolution Stock Analysis Notes
About 98.0% of the company shares are owned by institutional investors. The book value of Revolution Medicines was at this time reported as 11.16. The company recorded a loss per share of 4.01. Revolution Medicines had not issued any dividends in recent years. Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Revolution Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 212 people. To find out more about Revolution Medicines contact Mark Goldsmith at 650 481 6801 or learn more at https://www.revmed.com.Revolution Medicines Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Revolution Medicines' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Revolution Medicines or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Revolution Medicines generated a negative expected return over the last 90 days | |
| Net Loss for the year was (600.09 M) with loss before overhead, payroll, taxes, and interest of (679.95 M). | |
| Revolution Medicines currently holds about 461.43 M in cash with (557.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Revolution Medicines, Iambic Therapeutics Partner to Use AI for Novel RAS-Addicted Cancer Drug Discovery |
Revolution Medicines Upcoming and Recent Events
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Revolution Largest EPS Surprises
Earnings surprises can significantly impact Revolution Medicines' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-02-28 | 2021-12-31 | -0.64 | -0.71 | -0.07 | 10 | ||
2023-05-08 | 2023-03-31 | -0.81 | -0.72 | 0.09 | 11 | ||
2021-11-10 | 2021-09-30 | -0.63 | -0.72 | -0.09 | 14 |
Revolution Medicines Environmental, Social, and Governance (ESG) Scores
Revolution Medicines' ESG score is a quantitative measure that evaluates Revolution Medicines' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Revolution Medicines' operations that may have significant financial implications and affect Revolution Medicines' stock price as well as guide investors towards more socially responsible investments.
Revolution Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2025-03-31 | 5.6 M | Bvf Inc | 2025-03-31 | 5 M | Bellevue Group Ag | 2025-03-31 | 4.4 M | Geode Capital Management, Llc | 2025-03-31 | 4.1 M | Alphabet Inc | 2025-03-31 | 4.1 M | Woodline Partners Lp | 2025-03-31 | 3.9 M | Jpmorgan Chase & Co | 2025-03-31 | 3.7 M | Casdin Capital, Llc | 2025-03-31 | 3.7 M | Holocene Advisors, Lp | 2025-03-31 | 3.7 M | Vanguard Group Inc | 2025-03-31 | 16.6 M | Blackrock Inc | 2025-03-31 | 14.7 M |
Revolution Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.06 B.Revolution Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.25) | |
| Return On Equity | (0.26) | (0.28) |
Management Efficiency
Revolution Medicines has return on total asset (ROA) of (0.2309) % which means that it has lost $0.2309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3668) %, meaning that it created substantial loss on money invested by shareholders. Revolution Medicines' management efficiency ratios could be used to measure how well Revolution Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of July 26, 2025, Return On Tangible Assets is expected to decline to -0.25. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, Revolution Medicines' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 18.4 M, whereas Other Assets are forecasted to decline to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.50 | 14.18 | |
| Tangible Book Value Per Share | 13.08 | 13.73 | |
| Enterprise Value Over EBITDA | (11.76) | (12.35) | |
| Price Book Value Ratio | 3.24 | 3.08 | |
| Enterprise Value Multiple | (11.76) | (12.35) | |
| Price Fair Value | 3.24 | 3.08 | |
| Enterprise Value | 6.9 B | 7.3 B |
Revolution Medicines has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Technical Drivers
As of the 26th of July, Revolution Medicines holds the Coefficient Of Variation of 3473.0, semi deviation of 2.52, and Risk Adjusted Performance of 0.0296. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Revolution Medicines, as well as the relationship between them. Please check Revolution Medicines information ratio, and the relationship between the downside deviation and value at risk to decide if Revolution Medicines is priced some-what accurately, providing market reflects its current price of 37.91 per share. Given that Revolution Medicines has jensen alpha of (0.14), we recommend you to check out Revolution Medicines's recent market performance to make sure the company can sustain itself at a future point.Revolution Medicines Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Revolution Medicines middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Revolution Medicines. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Revolution Medicines Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Revolution Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Revolution Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Revolution Medicines insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Revolution Medicines Outstanding Bonds
Revolution Medicines issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Revolution Medicines uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Revolution bonds can be classified according to their maturity, which is the date when Revolution Medicines has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Revolution Medicines Predictive Daily Indicators
Revolution Medicines intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Revolution Medicines stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Revolution Medicines Corporate Filings
| 17th of July 2025 Other Reports | ViewVerify | |
F4 | 2nd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 30th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 23rd of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 18th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify |
Revolution Medicines Forecast Models
Revolution Medicines' time-series forecasting models are one of many Revolution Medicines' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Revolution Medicines' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Revolution Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Revolution Medicines prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Revolution shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Revolution Medicines. By using and applying Revolution Stock analysis, traders can create a robust methodology for identifying Revolution entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (43.69) | (41.50) | |
| Operating Profit Margin | (48.38) | (45.96) | |
| Net Loss | (43.34) | (41.17) | |
| Gross Profit Margin | 0.65 | 0.69 |
Current Revolution Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Revolution analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Revolution analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 72.36 | Strong Buy | 12 | Odds |
Most Revolution analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Revolution stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Revolution Medicines, talking to its executives and customers, or listening to Revolution conference calls.
Revolution Stock Analysis Indicators
Revolution Medicines stock analysis indicators help investors evaluate how Revolution Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Revolution Medicines shares will generate the highest return on investment. By understating and applying Revolution Medicines stock analysis, traders can identify Revolution Medicines position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 699.2 M | |
| Common Stock Shares Outstanding | 167.7 M | |
| Total Stockholder Equity | 2.3 B | |
| Total Cashflows From Investing Activities | -554.4 M | |
| Tax Provision | -753 K | |
| Property Plant And Equipment Net | 141.8 M | |
| Cash And Short Term Investments | 2.3 B | |
| Cash | 543.1 M | |
| Accounts Payable | 54.4 M | |
| Net Debt | -407.2 M | |
| 50 Day M A | 38.9369 | |
| Total Current Liabilities | 163.9 M | |
| Non Current Assets Total | 230.7 M | |
| Non Currrent Assets Other | 17.6 M | |
| Stock Based Compensation | 79.2 M |
Complementary Tools for Revolution Stock analysis
When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |